New research suggests that semaglutide, a popular diabetes and weight-loss drug, may reduce the risk of Alzheimer’s disease in people with type 2 diabetes. The study compared semaglutide to seven other anti-diabetic drugs and found it was linked to a significantly lower risk of developing Alzheimer’s.

A new trial reveals that weekly injections of the weight-loss drug Wegovy (semaglutide) lowered the risk of death from COVID-19 by about a third and reduced overall mortality by 19%. The study followed more than 17,000 participants with heart disease and obesity, showing that Wegovy decreased the likelihood of death from cardiovascular disease by 15% and other causes by 23%.